false
0001468492
0001468492
2026-03-16
2026-03-16
0001468492
hscs:CommonStockCustomMember
2026-03-16
2026-03-16
0001468492
hscs:WarrantsCustomMember
2026-03-16
2026-03-16
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): March 16, 2026
|
HEARTSCIENCES INC.
(Exact name of Registrant as Specified in Its Charter)
|
Texas
|
001-41422
|
26-1344466
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
| |
|
|
|
|
|
550 Reserve Street, Suite 360
|
|
|
Southlake, Texas
|
|
76092
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
|
Registrant’s Telephone Number, Including Area Code: 682 237-7781
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock
|
|
HSCS
|
|
The Nasdaq Stock Market LLC
|
|
Warrants
|
|
HSCSW
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On March 16, 2026, HeartSciences Inc. (the “Company”) issued a press release providing information regarding the Company’s financial and operating results for the quarter ended January 31, 2026, and other business updates. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated by reference herein.
The information contained in Item 2.02 of this Current Report and Exhibit 99.1 to this Current Report shall not be deemed to be “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filings made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
|
Exhibit
No.
|
|
Description
|
|
99.1*
|
|
Press Release dated January 31, 2026
|
|
Exhibit 104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
|
HEARTSCIENCES INC.
|
| |
|
|
|
| |
|
|
|
|
Date:
|
March 16, 2026
|
By:
|
/s/ Andrew Simpson
|
| |
|
|
Andrew Simpson
President, Chief Executive Officer and Chairman of the Board of Directors
|
Exhibit 99.1
HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Southlake, Texas — March 16, 2026 — HeartSciences Inc. (Nasdaq: HSCS), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today reported financial results for its fiscal third quarter ended January 31, 2026 (“FQ3 2026”) and provided a business update.
Third Quarter and Recent Highlights
During the third quarter and subsequent period, the Company continued advancing the commercialization of its MyoVista Insights™ healthcare IT platform and submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administration (“FDA”) for 510(k) premarket clearance.
MyoVista Insights™ Healthcare IT Software Platform
| |
●
|
Regulatory classification. MyoVista Insights is classified as a Medical Device Data System (“MDDS”), which carries significantly lower regulatory requirements than medical devices and is exempt from FDA 510(k) clearance. As a result, organizational costs and time to commercial rollout are expected to be substantially lower and faster than those associated with regulated medical devices.
|
| |
●
|
Platform advancement. Since its early-adopter launch in 2025, the Company has implemented phased upgrades to MyoVista Insights. On March 13, 2026, HeartSciences released a significant version upgrade ahead of the American College of Cardiology (“ACC”) Annual Scientific Session, where the Company will exhibit and publicly introduce the platform to the broader cardiology and healthcare IT community. The upgrade includes mobile phone viewing, reporting enhancements, and significant interoperability improvements designed to support deployment across large health systems.
|
| |
●
|
Commercial traction. During 2026 the Company’s objectives include establishing key reference sites and generating initial revenues. HeartSciences has already made commercial progress with reference installations and endorsement from a hospital network. Early feedback has been compelling, and the Company is currently in discussions with multiple health systems regarding deployment. Management expects to announce several key customer wins during 2026.
|
| |
●
|
AI-ECG marketplace opportunity. In addition to generating per-test SaaS revenues as a secure cloud-based ECG data management system, MyoVista Insights is purpose-built to enable the integration of AI-ECG algorithms directly into routine clinical practice through an AI-ECG marketplace. The platform is designed to host third-party algorithms alongside HeartSciences’ own technologies. The Company is currently in discussions with several potential partners to host AI algorithms and believes this model positions HeartSciences to participate in a multi-billion-dollar AI-ECG market opportunity while reducing the cost and time required for algorithm development and regulatory clearance.
|
| |
●
|
Investor demonstration. Following the public introduction of MyoVista Insights at the ACC Annual Scientific Session, the Company plans to host an investor call to demonstrate the platform and provide additional detail regarding its commercialization strategy and market opportunity.
|
MyoVista® wavECG™ Device
| |
●
|
The Company submitted its MyoVista wavECG device to the FDA for 510(k) premarket clearance in December 2025.
|
| |
●
|
HeartSciences elected to separate the FDA submissions for the MyoVista wavECG device and its impaired cardiac relaxation AI-ECG algorithm following updated guidance published by the American Society of Echocardiography (“ASE”) regarding the assessment of Left Ventricular Diastolic Dysfunction (“LVDD”), including revised age-based thresholds for cardiac relaxation (e’).
|
Management Commentary
Andrew Simpson, Chief Executive Officer of HeartSciences, said:
“We are making strong progress toward our 2026 objectives, including establishing reference sites, commencing revenue generation for MyoVista Insights, making AI algorithms available on the platform, and achieving best-in-class interoperability across hospital systems.”
Mr. Simpson added, “The submission of the MyoVista wavECG device to the FDA represents an important regulatory milestone and advances our broader strategy to modernize ECG through the integration of artificial intelligence.”
Fiscal Third Quarter 2026 Financial Results
HeartSciences reported no meaningful revenue for FQ3 2026 as the Company continues to focus on commercialization of the MyoVista Insights platform.
As of January 31, 2026, the Company had approximately $3.4 million in cash and cash equivalents and $2.7 million in shareholders’ equity.
Complete financial results are included in the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2026, which has been filed with the U.S. Securities and Exchange Commission and is available on the Company’s website at
www.heartsciences.com.
About HeartSciences
HeartSciences is a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the integration of artificial intelligence (“AI”). The Company’s MyoVista Insights platform is a device-agnostic, next-generation ECG management system designed to improve clinical efficiency and decision-making. Its MyoVista wavECG device is designed to deliver conventional ECG functionality while supporting on-device AI-enabled solutions
For more information, please visit: https://www.heartsciences.com. X: @HeartSciences
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' Annual Report on Form 10-K for the fiscal year ended April 30, 2025, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 24, 2025, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2025 filed with the SEC on September 11, 2025, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended October 31, 2025 filed with the SEC on December 15, 2025, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2026 filed with the SEC on March 16, 2026, and in HeartSciences' other filings with the SEC at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Investor Relations:
Integrous Communications
Mark Komonoski, Partner
Phone: 877 255 8483
Email: mkomonoski@integcom.us
Media Contact:
HeartSciences
Gene Gephart
+1 682 244 2578 Ext. 2024
info@heartsciences.com
